Why the study?
Does the manufacturing process of solvent/detergent factor VIII reduce or inactivate hepatitis A virus in spiked human plasma?
Does the manufacturing process of solvent/detergent factor VIII reduce or inactivate hepatitis A virus in spiked human plasma?
Answers are grounded in this paper and cite their sources.
The manufacturing process for solvent/detergent factor VIII concentrate effectively reduces hepatitis A virus infectivity by 5.5 to 8.55 log10.
Recent reports have suggested an increased risk of type A viral hepatitis in hemophilic patients treated with high purity factor VIII concentrates prepared using ion exchange chromatography coupled with solvent/detergent treatment for inactivation of viruses. To determine the capacity for removal or inactivation of hepatitis A virus during the factor VIII manufacturing process, human plasma and various factor VIII production intermediates were spiked with cell culture-propagated virus and subjected to scaled down conditions mimicking the manufacture of solvent/detergent factor VIII. The combination of antibody-mediated neutralization, cryoprecipitation, anion exchange chromatography, and lyophilization in the absence of sucrose resulted in a minimal reduction of 5.5 to 8.55 log10 in the infectivity of hepatitis A virus.
No takes yet. Share an insight, caveat, or question.
Lemon et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: